AI Engines For more Details: Perplexity Kagi Labs You
Smooth Muscle Relaxation: Camylofine hydrochloride acts as an antispasmodic agent by relaxing smooth muscles in the gastrointestinal tract. This helps to alleviate symptoms such as abdominal pain, cramping, and discomfort associated with conditions like IBS, colitis, and functional dyspepsia.
Relief of GI Symptoms: By reducing muscle spasms and contractions in the GI tract, camylofine hydrochloride can relieve symptoms such as abdominal cramps, bloating, and discomfort. It may also help to regulate bowel movements in individuals with IBS.
Improvement in Digestive Function: Camylofine hydrochloride may improve digestive function by reducing the frequency and severity of symptoms related to GI motility disorders. This can lead to better absorption of nutrients and overall gastrointestinal health.
Treatment of Dysmenorrhea: In addition to its use in GI disorders, camylofine hydrochloride may also be used to relieve menstrual cramps (dysmenorrhea) by relaxing uterine smooth muscles. This can help reduce the intensity and duration of menstrual pain.
Adjunctive Therapy: Camylofine hydrochloride may be used as adjunctive therapy alongside other medications or lifestyle modifications for the management of GI disorders. It is often prescribed in combination with dietary changes, stress management techniques, and other medications to optimize symptom control.
Sedative Effects: Some individuals may experience mild sedation or drowsiness while taking camylofine hydrochloride, although this effect is generally less pronounced compared to other antispasmodic agents. It is important to avoid activities that require mental alertness, such as driving or operating heavy machinery, until the individual's response to the medication is known.
Potential Side Effects: Common side effects of camylofine hydrochloride may include dry mouth, blurred vision, constipation, dizziness, and urinary retention. These side effects are usually mild and transient but should be reported to a healthcare provider if they persist or worsen.
Contraindications: Camylofine hydrochloride is contraindicated in individuals with hypersensitivity to the medication, glaucoma, urinary retention, severe ulcerative colitis, myasthenia gravis, and certain other medical conditions. It should be used with caution in elderly individuals and those with impaired hepatic or renal function.
Dosage and Administration: The dosage of camylofine hydrochloride may vary depending on the individual's age, medical condition, and response to treatment. It is typically taken orally as tablets or capsules, with or without food, as directed by a healthcare provider.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 1.6 | 0.9 | 0.78 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 1.3 | 0.5 | 1.6 |
| Allergies | 2.2 | 0.8 | 1.75 |
| Allergy to milk products | 0.7 | 0.6 | 0.17 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 2.7 | 4 | -0.48 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.1 | 17 |
| Ankylosing spondylitis | 1.9 | 0.6 | 2.17 |
| Anorexia Nervosa | 0.4 | 1.3 | -2.25 |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 2.6 | 1.1 | 1.36 |
| Atherosclerosis | 0.6 | 0.2 | 2 |
| Atrial fibrillation | 2.4 | 1.5 | 0.6 |
| Autism | 4.4 | 3.9 | 0.13 |
| Autoimmune Disease | 0.3 | 0.3 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.9 | 0.9 | 0 |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.6 | 1 | -0.67 |
| Carcinoma | 2.2 | 1.6 | 0.38 |
| Celiac Disease | 0.9 | 2.7 | -2 |
| Cerebral Palsy | 0.9 | 0.4 | 1.25 |
| Chronic Fatigue Syndrome | 2.1 | 4.4 | -1.1 |
| Chronic Kidney Disease | 2.3 | 2.1 | 0.1 |
| Chronic Lyme | 0.1 | 0.3 | -2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.9 | -0.5 |
| Chronic Urticaria (Hives) | 0.3 | 0.1 | 2 |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Cognitive Function | 1.6 | 0.6 | 1.67 |
| Colorectal Cancer | 3.1 | 0.9 | 2.44 |
| Constipation | 0.6 | 0.1 | 5 |
| Coronary artery disease | 0.3 | 1.9 | -5.33 |
| COVID-19 | 3.2 | 4.5 | -0.41 |
| Crohn's Disease | 2.8 | 3.1 | -0.11 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | -0.7 | |
| deep vein thrombosis | 0.5 | 0.3 | 0.67 |
| Denture Wearers Oral Shifts | 0 | 0 | |
| Depression | 4.5 | 5 | -0.11 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 1.6 | 1.2 | 0.33 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.8 | 0.9 | -0.13 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 1.3 | 1.2 | 0.08 |
| Functional constipation / chronic idiopathic constipation | 1.9 | 1.7 | 0.12 |
| gallstone disease (gsd) | 1 | 0.4 | 1.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.7 | -1.33 |
| Generalized anxiety disorder | 1.1 | 1.1 | 0 |
| Gout | 0.9 | 0.4 | 1.25 |
| Graves' disease | 0.9 | 1.9 | -1.11 |
| Gulf War Syndrome | 0.4 | 0.5 | -0.25 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 2.2 | 1.8 | 0.22 |
| Heart Failure | 0.9 | 1.1 | -0.22 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.1 | 2 |
| hyperglycemia | 0.6 | 0.9 | -0.5 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.4 | 2 | 0.2 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 1.2 | 0.3 | 3 |
| IgA nephropathy (IgAN) | 0.6 | 1.1 | -0.83 |
| Inflammatory Bowel Disease | 1.9 | 4.1 | -1.16 |
| Insomnia | 1.6 | 1.5 | 0.07 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.4 | 0.6 | -0.5 |
| Irritable Bowel Syndrome | 2.6 | 1.9 | 0.37 |
| ischemic stroke | 1.2 | 0.6 | 1 |
| Liver Cirrhosis | 3.1 | 2.8 | 0.11 |
| Long COVID | 3.2 | 3.6 | -0.13 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.4 | 0.9 | -1.25 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.2 | 2 | -9 |
| ME/CFS without IBS | 0.6 | 1.5 | -1.5 |
| Menopause | 0.5 | 0.1 | 4 |
| Metabolic Syndrome | 3.2 | 3.2 | 0 |
| Mood Disorders | 4.1 | 4.1 | 0 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.1 | 3 |
| Multiple Sclerosis | 2.2 | 2.1 | 0.05 |
| Multiple system atrophy (MSA) | 0.2 | 0.4 | -1 |
| neuropathic pain | 0.3 | 1.2 | -3 |
| Neuropathy (all types) | 0.5 | 0.2 | 1.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.9 | 3 | -0.58 |
| NonCeliac Gluten Sensitivity | 1.1 | 0.6 | 0.83 |
| Obesity | 4.9 | 4.1 | 0.2 |
| obsessive-compulsive disorder | 1.7 | 2.9 | -0.71 |
| Osteoarthritis | 0.4 | 0.6 | -0.5 |
| Osteoporosis | 0.9 | 1.1 | -0.22 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 3.7 | 3.1 | 0.19 |
| Polycystic ovary syndrome | 1.4 | 1.4 | 0 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | |
| primary biliary cholangitis | 0.9 | 0.9 | |
| Primary sclerosing cholangitis | 0.6 | 0.9 | -0.5 |
| Psoriasis | 1.1 | 1.3 | -0.18 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 2.8 | 0.07 |
| Rosacea | 0.9 | 0.3 | 2 |
| Schizophrenia | 2.8 | 1.6 | 0.75 |
| scoliosis | 0.3 | 0.5 | -0.67 |
| Sjögren syndrome | 0.7 | 1.6 | -1.29 |
| Sleep Apnea | 1.6 | 1 | 0.6 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.2 | 3.5 |
| Stress / posttraumatic stress disorder | 1.2 | 1.3 | -0.08 |
| Systemic Lupus Erythematosus | 1.9 | 1 | 0.9 |
| Tic Disorder | 0.3 | 0.9 | -2 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 1.7 | 1.4 | 0.21 |
| Type 2 Diabetes | 3.2 | 2.5 | 0.28 |
| Ulcerative colitis | 1.9 | 2.1 | -0.11 |
| Unhealthy Ageing | 3 | 1.5 | 1 |
| Vitiligo | 0.9 | 1 | -0.11 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
